Ratings Johnson & Johnson Deutsche Boerse AG

Equities

JNJ

US4781601046

Market Closed - Deutsche Boerse AG Other stock markets 11:59:19 2024-06-07 am EDT			5-day change	1st Jan Change
137.1 ^EUR	+2.13%		+1.15%	-3.27%

12:18am	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
Jun. 07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With an enterprise value anticipated at 3.93 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	-3.27%	354B	-
ELI LILLY AND COMPANY	+45.82%	765B	C+
NOVO NORDISK A/S	+40.95%	632B	B
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	299B	C+
ASTRAZENECA PLC	+18.45%	248B	B+
ROCHE HOLDING AG	-0.78%	219B	A+
NOVARTIS AG	+11.88%	216B	B-
AMGEN INC.	+5.90%	164B	C+
PFIZER, INC.	-0.73%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes